Isavuconazole丨CAS 241479-67-4

Isavuconazole is a triazole antifungal agent widely used in the treatment and prevention of severe systemic fungal infections. It is primarily applied in the management of invasive aspergillosis and mucormycosis, conditions that typically affect immunocompromised patients. The compound functions by inhibiting the fungal enzyme lanosterol 14α-demethylase, a critical catalyst in ergosterol biosynthesis, thereby disrupting fungal cell membrane integrity and inhibiting fungal growth. In clinical practice, Isavuconazole is available as both an intravenous and oral formulation, offering flexible therapeutic options for hospital and outpatient settings. Beyond its approved therapeutic uses, it serves as a reference standard and research compound in pharmaceutical studies focused on antifungal drug development, pharmacokinetics, and resistance mechanisms.

The benefits of Isavuconazole lie in its potent antifungal activity, favorable pharmacokinetic profile, and improved safety compared to older azole antifungals. It exhibits broad-spectrum efficacy against Aspergillus and Mucorales species, making it a critical option for treating life-threatening fungal infections. Its high oral bioavailability, predictable absorption, and long half-life allow for once-daily dosing, improving patient compliance and treatment convenience. Unlike some earlier triazoles, Isavuconazole demonstrates reduced risk of hepatotoxicity and QT interval prolongation, contributing to a more favorable safety profile. The compound also shows minimal interaction with food and moderate drug–drug interaction potential, supporting its use in complex clinical regimens. Its stability and bioefficacy make it well suited for both acute and long-term antifungal therapy.